CD19 CAR therapy is predicated on advances in genetic engineering, T cell biology, tumor immunology, synthetic biology, target identification, cell manufacturing sciences, and regulatory compliance the central tenets of CAR therapy.
Like synthetic cannabinoids, the identification of these compounds, of course, cannot be performed using these methods; moreover, the detection of small amounts or mixtures of cathinones is difficult.
Raman spectroscopy is a suitable technique for the in situ non-destructive identification of synthetic organic pigments in the presence of the complex binding media characteristic of synthetic resin paints or colour lithographic inks.
Until recently, the identification of synthetic lethal interactions in human cells was based on screens using chemical libraries or on inferred synthetic lethality in model organisms such as S. cerevisiae[ 1].
Identification of synthetic peptide substrates for novel peptidases is an essential step for their study.
Here, we have discussed the major considerations involved in designing a CRISPR/Cas9 based screening experiment for identification of synthetic lethal targets.
Finally, some studies using CRISPR/Cas9 for genome-wide knockout screening in human cells and computational approaches for identification of synthetic lethal interactions have been discussed.
As a result, directed evolution remains a valuable tool for synthetic biology, enabling the identification of desired functionalities from large libraries of variants.
Flow cytometry is a powerful, high-throughput library screening tool in numerous applications including the isolation of bioactive molecules from synthetic combinatorial libraries, the identification of virulence genes in microorganisms, and the study and engineering of protein functions.
Identification of synthetic or non-endogenous ligands remains critical as those compounds serve as important experimental tools and provide critical mechanistic insights into the function of nuclear receptors.
